Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Chinese Journal of Cancer Research
Published in: Chinese Journal of Cancer Research 2/2011

01-06-2011 | Original Article

Immediate versus delayed treatment with EGFR tyrosine kinase inhibitors after first-line therapy in advanced non-small-cell lung cancer

Authors: Zhi-jie Wang, Tong-tong An, Tony Mok, Lu Yang, Hua Bai, Jun Zhao, Jian-chun Duan, Mei-na Wu, Yu-yan Wang, Ping-ping Li, Hong Sun, Ping Yang, Jie Wang

Published in: Chinese Journal of Cancer Research | Issue 2/2011

Login to get access
Metadata
Title
Immediate versus delayed treatment with EGFR tyrosine kinase inhibitors after first-line therapy in advanced non-small-cell lung cancer
Authors
Zhi-jie Wang
Tong-tong An
Tony Mok
Lu Yang
Hua Bai
Jun Zhao
Jian-chun Duan
Mei-na Wu
Yu-yan Wang
Ping-ping Li
Hong Sun
Ping Yang
Jie Wang
Publication date
01-06-2011
Publisher
Chinese Anti-Cancer Association
Published in
Chinese Journal of Cancer Research / Issue 2/2011
Print ISSN: 1000-9604
Electronic ISSN: 1993-0631
DOI
https://doi.org/10.1007/s11670-011-0112-5

Other articles of this Issue 2/2011

Chinese Journal of Cancer Research 2/2011 Go to the issue

Original Article

Effects of an engineered anti-HER2 antibody chA21 on invasion of human ovarian carcinoma cell in vitro

Original Article

Procyanidins inhibit tumor angiogenesis by crosslinking extracellular matrix

Original Article

DNA methylation profiles of protease nexin 1 (SERPINE2) gene in human cell lines

Review Article

DNA repair gene polymorphisms in the nucleotide excision repair pathway and lung cancer risk: A meta-analysis

Original Article

The use of CT perfusion to determine microvessel density in lung cancer: Comparison with FDG-PET and pathology

Original Article

Breast cancer subtypes and survival in Chinese women with operable primary breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits